Biotechnology - Provenge

Filter

Current filters:

Provenge

Popular Filters

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

Dendreon shares fall as company warns of worry over debt repayment

Dendreon shares fall as company warns of worry over debt repayment

13-08-2014

Shares of US biotech firm Dendreon have fallen after it warned shareholders about debt problems.

BiotechnologyBusiness FinanceCancer vaccinesDendreonFinancialProvengeSipuleucel-TUSA

Dendreon chief to step down for personal reasons

Dendreon chief to step down for personal reasons

10-06-2014

US biotech firm Dendreon revealed last evening that John Johnson plans to step down as president and…

BiotechnologyBoardroomDendreonManagementProvenge

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

12-04-2014

US biotech firm Dendreon has released positive preliminary data from a long-term analysis of the Phase…

BiotechnologyDendreonOncologyProvengeResearch

Dendreon leaps as it sets out plan to launch Provenge in Europe

Dendreon leaps as it sets out plan to launch Provenge in Europe

04-03-2014

US biotech firm Dendreon says it plans to make its prostate cancer drug Provenge (autologous peripheral…

BiotechnologyDendreonEuropeMarkets & MarketingOncologyProvenge

Dendreon restructures, following poor third-quarter Provenge sales

Dendreon restructures, following poor third-quarter Provenge sales

13-11-2013

USA-based biotech firm Dendreon revealed yesterday that it is implementing a restructuring and cost reduction…

BiotechnologyDendreonFinancialOncologyProvenge

Back to top